2 Growth Stocks to Buy With Less Than $100

Core Viewpoint - The article highlights two growth stocks, Shopify and Exelixis, that are trading under $100 and present attractive investment opportunities due to their solid growth prospects and market positions [2][3]. Group 1: Shopify - Shopify aims to establish itself as a long-term player in the e-commerce industry, which has significant growth potential, with e-commerce sales currently accounting for only 16% of U.S. retail sales [4][5]. - The company provides a platform for businesses to create online storefronts, benefiting from high switching costs due to the customization efforts made by merchants [5]. - Shopify's revenue increased by 21% year-over-year to $2 billion, with a gross margin of 51.1%, up from 49.3% in the previous year [6]. - Free cash flow surged by 243% to $333 million, with a free cash flow margin of 16%, compared to 6% in the prior-year quarter [7]. - The company reported net earnings per share (EPS) of $0.13, a significant improvement from a loss of $1.02 per share in the previous year [7]. - Despite a forward price-to-sales ratio of 11.9, which is considered high, the long-term growth prospects justify the premium for growth-oriented investors [8]. Group 2: Exelixis - Exelixis is a mid-cap biotech company focused on oncology, with its leading product, Cabometyx, being the top-prescribed therapy for renal cell carcinoma and approved for other cancers [9][10]. - The company's total revenue grew by 35.6% year-over-year to $637.2 million, with U.S. sales of Cabometyx reaching $437.6 million, an increase of nearly 7% [10]. - Exelixis reported an EPS of $0.77, a significant rise from $0.25 in the previous year, and is pursuing label expansions for Cabometyx in various cancer treatments [11]. - The company is conducting phase 3 studies for a new product, zanzalintinib, targeting colorectal cancer, which has a significant unmet medical need [13]. - Exelixis maintains a strong pipeline and consistent financial growth, distinguishing itself from many peers in the biotech sector that lack marketable products [14].